Shionogi Inc.
Basic information
- Head office
- 5-54 Oosakami, Kita-ku, Osaka City, Grangreen Osaka South Building Park Tower
- Chief executive
- Isao Teshiyagi
- Capital
- 21,279,742,717 JPY (212 100 millionJPY)
- Employees (non-consolidated)
- Employees (consolidated)
- 4,959 people
- Start date
- 1919-06-05
- End date
Websites
Business
Related companies
—
Network
History
Founder Shionogi Saburo established Shionogi Saburo Trading Company in Osaka Midoshi-cho, selling traditional Japanese and Western medicines.![]()
Shionogi Saburo founded the pharmaceutical wholesaler Shionogi Saburo Store on March 17, 1878, at 3-12 Doushou-cho, Osaka.![]()
Produced and sold the first in-house new drug, antacid 'Antacidjin', and registered the 'Bun-Do' mark as a trademark.![]()
In 1909, Choujiro began trial production of an antacid and commercialized the stomach acid neutralizer Antachijin.![]()
In 1910, built the Shionogi Pharmaceutical Factory and intensified new drug development and manufacturing.![]()
In 1912, launched the heart drug Digitammin, a productized Digitaris preparation introduced by Kondo Heisaburo.![]()
Merged Shionogi Saburo Trading Company and Shionogi Pharmaceutical Factory, reorganized as Shionogi Shoten Co., Ltd.![]()
In 1919, Shionogi Saburo Store and Shionogi Pharmaceutical Factory merged to establish Shionogi Co., Ltd.![]()
Established Kuse Factory in Amagasaki, Hyogo Prefecture (now Kuse Business Office), and set up a laboratory within the factory.![]()
In 1945, post-war inflation and economic turmoil worsened management; Gisaburo promoted technology improvement and cost reduction to improve management.![]()
In 1957, we inherited a corporate culture that emphasized creating better products, selling them accurately, and focusing on technological development.![]()
In 1958, we transferred plant medicines, animal medicines, and pharmaceutical wholesale to other companies, consolidating our pharmaceutical business.![]()
Constructed Central Research Institute in Fukushima-ku, Osaka City (now consolidated into the Pharmaceutical Research Center).![]()
Established Animal Pharmaceutical Department and Plant Pharmaceutical Department (transferred), started clinical laboratory (transferred), and established Shionogi Pharmaceutical Taiwan (stock).![]()
Construction of Medical Science Research Institute (within Settsu plant site); launch of 'Fullmarin'![]()
Establishment of Shionogi Comprehensive Services Co., Ltd.; acquisition of capsule business from Eli Lilly (later sold)![]()
Establishment of Shionogi Code of Conduct; establishment of Oomori Pharmaceutical Co., Ltd. (later sold); establishment of Musho Pharmaceutical Co., Ltd. (later sold)![]()
In 1998, we acquired the Chinese pharmaceutical company C&O Pharmaceutical Technology (Holdings) Limited.![]()
Establishment of Shionogi USA, Inc.; establishment of Shionogi-GlaxoSmithKline Pharmaceuticals LLC (later Shionogi-ViiV Healthcare LLC); start of joint research on HIV treatment drugs![]()
Acquisition of US-based Sciele Pharma; launch of 'Irbetan', 'Defirin', 'Pirespa'; opening of joint research facility with Hokkaido University![]()
Third medium-term management plan started; launch of 'Rapialact' and 'Sainbarta'; establishment of research institute![]()
In 2010, we formulated a new mid-term management plan and aimed for growth as a drug discovery pharmaceutical company.![]()
In 2011, we acquired the Chinese pharmaceutical company C&O Pharmaceutical Technology (Holdings) Limited.![]()
In 2014, we started a new mid-term management plan aimed at growth as a drug discovery pharmaceutical company.![]()
Establishment of multiple subsidiaries, launch of Mesapain, Inchunib, Symproic, Suinproik, Oxycodone TR tablets![]()
Establishment of Shionogi Pharma, European subsidiary Shionogi B.V., launch of Zoflura, Mulpleta, Jaruka![]()
Establishment of M3 joint venture, UMN Pharma subsidiary, opening of training center, launch of Rizmoic, Shufukou, Bivance![]()
News
There is no news.